Salima Hacein-Bey-Abina appointed Chair of AFM-Téléthon’s 11th Scientific Advisory Board

Professor Salima Hacein-Bey-Abina took up her role as Chair of AFM-Téléthon’s 11th Scientific Advisory Board on 17 November 2026. She succeeds geneticist Judith Melki, whom AFM-Téléthon thanks for her commitment to families over the past three years.
A professor and hospital consultant in immunology, Salima Hacein-Bey-Abina is an internationally recognised expert in gene therapy and cell therapy. She brings both a scientific and a clinical perspective to the Board at a time when the number of potential treatments and clinical trials is growing.
A pioneer in gene therapy for severe immunodeficiencies
Alongside Professors Alain Fischer and Marina Cavazzana, Professor Salima Hacein-Bey-Abina helped pioneer the development of gene therapies for severe immunodeficiencies. She contributed to the first clinical success of gene therapy in 2000 in children with X-linked severe combined immunodeficiency (SCID-X1), known as ‘bubble babies’.
At Necker Hospital, she continued to develop several clinical trials and gained extensive expertise in cell therapy and haematopoietic stem cell transplantation for the treatment of immunodeficiencies and blood disorders.
She also has extensive experience in clinical immunology, having developed and led the Biological Immunology Department at Bicêtre Hospital. She now heads the Immunology and Histocompatibility Department at Saint-Louis Hospital and leads the Immunology and Immunotherapies research team at the UTCBS research unit (Inserm U1267, CNRS UMR 8258).
Her experience across fundamental research, translational development and clinical practice will help support AFM-Téléthon’s scientific priorities and its efforts to make therapeutic advances available to as many patients as possible.
"It is a great honour for me to take on the role of Chair of AFM-Téléthon’s Scientific Advisory Board. AFM-Téléthon is much more than a charity that supports research. It champions the cause of people and families facing serious, disabling diseases that often still have no treatment. It also plays a role in developing innovative therapies. I am delighted to contribute to this work alongside the members of the Scientific Advisory Board." Professor Salima Hacein-Bey-Abina
The role of AFM-Téléthon’s Scientific Advisory Board
The Scientific Advisory Board brings together 83 volunteer experts from the international scientific community. It reviews research proposals submitted to AFM-Téléthon, including through its calls for proposals, and commissions external reviews. It advises AFM-Téléthon’s Board of Directors, which makes the final decision.
The Scientific Advisory Board also proposes areas for further research and assesses the scientific quality of projects before and after they are carried out. It draws on an international network of 6,000 external experts. AFM-Téléthon funds an average of 350 research projects each year.
Read more : Our organization
